Management of blood glucose levels in oncological patients scheduled for FDG PET/CT examination

Objective: To determine the prevalence of abdominal involvement, distribution pattern and evaluate role of hybrid molecular imaging in patients with abdominal sarcoidosis. Methods: Between January 2010 and December 2011, 98 patients with chronic sarcoidosis and presence of prolonged symptoms or other findings suggestive of active disease were referred to FDG PET/CT examination. Active disease was found in 82 patients, and they all were screened for the presence of abdominal sarcoidosis on FDG PET/CT. All patients also underwent MDCT and assessment of serum ACE level. Follow up FDG PET/CT examination was done 12.3±5.4 months after the baseline. Results: Abdominal sarcoidosis was present in 31/82 patients with active sarcoidosis. FDG uptake was present in: retroperitoneal lymph nodes (77%), liver (26%), spleen (23%), adrenal gland (3%). Majority of patients had more than two locations of disease. Usually thoracic disease was spread into the extrathoracic localizations, while isolated abdominal sarcoidosis was present in 10% of patients. After first FDG PET/CT examination therapy was changed in all patients. Eleven patients came to the follow up examination where SUVmax significantly decreased in the majority of them. Three patients had total remission, three had absence of abdominal disease but discrete findings in thorax and others had less spread disease. ACE levels did not correlate with SUVmax level. Conclusion: FDG PET/CT can be a useful tool for detection of abdominal sarcoidosis and in the evaluation of therapy response in these patients. Awareness of the presence of intra-abdominal sarcoidosis is important in order to prevent long-standing unrecognized disease.

Download Full-text

Patient Experience of an 18F-FDG-PET/CT Examination: Need for Improvements in Patient Care

Journal of Radiology Nursing ◽

10.1016/j.jradnu.2014.11.008 ◽

2015 ◽

Vol 34 (2) ◽

pp. 100-108 ◽

Cited By ~ 2

Author(s):

Camilla Andersson ◽

Birgitta Johansson ◽

Cecilia Wassberg ◽

Silvia Johansson ◽

Håkan Ahlström ◽

...

Keyword(s):

Patient Care ◽

Patient Experience ◽

Fdg Pet ◽

Ct Examination ◽

Pet Ct ◽

18F Fdg ◽

Fdg Pet Ct

Download Full-text

Fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis, assessment of disease activity and therapeutic response in relapsing polychondritis

Rheumatology ◽

10.1093/rheumatology/kez243 ◽

2019 ◽

Vol 59 (1) ◽

pp. 99-106 ◽

Cited By ~ 3

Author(s):

Aman Sharma ◽

Rajender Kumar ◽

Adarsh MB ◽

G S R S N K Naidu ◽

Vikas Sharma ◽

...

Keyword(s):

Disease Activity ◽

Fdg Pet ◽

Therapeutic Response ◽

Clinical Symptoms ◽

Relapsing Polychondritis ◽

Response To Therapy ◽

Ct Examination ◽

Pet Ct ◽

Fdg Pet Ct ◽

Assessment Of Disease Activity

Abstract Objective To evaluate 18F-fluorodeoxyglucose (FDG) PET/CT in the assessment of disease activity, extent of the disease and response to therapy in relapsing polychondritis. Methods Twenty-five patients (9 men, 16 women) with a mean age of 38.2 years (s.d. 13.7; range 18–62), diagnosed to have relapsing polychondritis according to Damiani and Levine’s modification of McAdam’s criteria, who underwent PET/CT examination were included. Ten patients underwent a second PET/CT examination after therapy or during follow-up. Clinical symptoms and auxiliary examination findings were recorded. PET/CT findings were reviewed and correlated with the clinical symptoms. Results The major symptoms were aural pain (n = 21), nasal pain (n = 10), stridor (n = 5), cough (n = 9), fever (n = 8) and laryngeal tenderness (n = 8). The initial PET/CT was positive in 23/25 patients. PET/CT revealed involvement of auricular (n = 14), nasal (n = 8), laryngeal (n = 7), tracheobronchial (n = 6) and Eustachian (n = 3) cartilages with a mean maximum standardized uptake value (SUVmax) of 4.1 (s.d. 2.5; range 1.7–12.7). Fair correlation of aural/nasal pain/stridor with FDG avidity of cartilage involvement on PET/CT was noted. The key finding was detection of asymptomatic large airway involvement in seven patients (28%). Re-examination PET in 10 patients revealed complete therapeutic response (n = 5), partial response (n = 1), stable disease (n = 1), progressive disease (n = 1) and disease recurrence (n = 2). Conclusion FDG PET/CT is a useful tool for the assessment of the disease activity and extent. It identified activity in clinically inaccessible sites that are of clinical significance. It is also useful in assessing treatment response and finding relapse.

Download Full-text